Eliford Ngaimisi Kitabi
Eliford Ngaimisi Kitabi
Center for Translational Medicine, University of Maryland Baltimore
Verified email at fda.hhs.gov - Homepage
Title
Cited by
Cited by
Year
Long‐term efavirenz autoinduction and its effect on plasma exposure in HIV patients
E Ngaimisi, S Mugusi, OM Minzi, P Sasi, KD Riedel, A Suda, N Ueda, ...
Clinical Pharmacology & Therapeutics 88 (5), 676-684, 2010
1142010
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa …
E Ngaimisi, A Habtewold, O Minzi, E Makonnen, S Mugusi, W Amogne, ...
PloS one 8 (7), e67946, 2013
1102013
Effect of Rifampicin and CYP2B6 Genotype on Long‐Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis
E Ngaimisi, S Mugusi, O Minzi, P Sasi, KD Riedel, A Suda, N Ueda, ...
Clinical Pharmacology & Therapeutics 90 (3), 406-413, 2011
792011
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania
S Mugusi, E Ngaimisi, M Janabi, O Minzi, M Bakari, KD Riedel, ...
PloS one 7 (7), e40180, 2012
682012
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania
S Mugusi, E Ngaimisi, M Janabi, O Minzi, M Bakari, KD Riedel, ...
PloS one 7 (7), e40180, 2012
682012
β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans
RJ Hardwick, W Amogne, S Mugusi, G Yimer, E Ngaimisi, A Habtewold, ...
The Journal of infectious diseases 206 (7), 1012-1019, 2012
462012
CYP2B6* 6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria …
BA Maganda, OMS Minzi, E Ngaimisi, AAR Kamuhabwa, E Aklillu
The pharmacogenomics journal 16 (1), 88-95, 2016
352016
Frequency of the SLCO1B1 388A> G and the 521T> C polymorphism in Tanzania genotyped by a new LightCycler®-based method
E Aklillu, S Mugusi, E Ngaimisi, MM Hoffmann, S König, V Ziesenitz, ...
European journal of clinical pharmacology 67 (11), 1139-1145, 2011
342011
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment
BA Maganda, E Ngaimisi, AAR Kamuhabwa, E Aklillu, OMS Minzi
Malaria journal 14 (1), 1-11, 2015
312015
CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans
E Aklillu, L Odenthal-Hesse, J Bowdrey, A Habtewold, E Ngaimisi, ...
BMC infectious diseases 13 (1), 1-10, 2013
312013
Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product
OMS Minzi, IA Marealle, S Shekalaghe, O Juma, E Ngaimisi, M Chemba, ...
Malaria journal 12 (1), 1-8, 2013
212013
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment
E Ngaimisi, O Minzi, S Mugusi, P Sasi, KD Riedel, A Suda, N Ueda, ...
Journal of Antimicrobial Chemotherapy 69 (12), 3311-3319, 2014
202014
SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine
E Aklillu, A Habtewold, E Ngaimisi, G Yimer, S Mugusi, W Amogne, ...
Omics: a journal of integrative biology 20 (9), 538-545, 2016
192016
Copy number variation of Fc gamma receptor genes in HIV-infected and HIV-tuberculosis co-infected individuals in sub-Saharan Africa
LR Machado, J Bowdrey, E Ngaimisi, A Habtewold, O Minzi, E Makonnen, ...
PloS one 8 (11), e78165, 2013
192013
Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania.
SF Mugusi, E Ngaimisi, MY Janabi, FM Mugusi, O Minzi, PG Sasi, ...
Antiviral therapy 17 (2), 265-74, 2012
182012
Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa
G Pillai, G Davies, P Denti, JL Steimer, H McIlleron, S Zvada, E Chigutsa, ...
CPT: pharmacometrics & systems pharmacology 2 (8), 1-4, 2013
172013
Inter-laboratory development and cross validation of a chromatographic method for determination of lumefantrine in human plasma-A proficient capacity assessment of …
OM Minzi, E Ngaimisi, DH Shewiyo, P Sasi, AM Ignace
J Anal Bioanal Tech 3, 131, 2012
152012
Bioanalytical method for determination of nevirapine in-vivo in resource constrained laboratories
OMS Minzi, E Ngaimisi
J Chem Pharm Res 2, 431-9, 2010
112010
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
S Mugusi, E Ngaimisi, M Janabi, F Mugusi, O Minzi, E Aris, M Bakari, ...
European journal of clinical pharmacology 74 (11), 1405-1415, 2018
72018
Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study
A Bhatia, S Tawade, M Mastim, EN Kitabi, M Gopalakrishnan, M Shah, ...
Acta diabetologica 55 (5), 461-468, 2018
62018
The system can't perform the operation now. Try again later.
Articles 1–20